BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoffmann S, Kohler S, Ziegler A, Meisel A. Glucocorticoids in myasthenia gravis - if, when, how, and how much? Acta Neurol Scand 2014;130:211-21. [DOI: 10.1111/ane.12261] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chan ED, Chan MM, Chan MM, Marik PE. Use of glucocorticoids in the critical care setting: Science and clinical evidence. Pharmacology & Therapeutics 2020;206:107428. [DOI: 10.1016/j.pharmthera.2019.107428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
2 Lee YG, Kim US. Efficacy and Safety of Low-to-Moderate Dose Oral Corticosteroid Treatment in Ocular Myasthenia Gravis. J Pediatr Ophthalmol Strabismus 2018;55:339-42. [DOI: 10.3928/01913913-20180620-01] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
3 Qi G, Liu P, Dong H, Gu S, Yang H, Xue Y. Metastatic Thymoma-Associated Myasthenia Gravis: Favorable Response to Steroid Pulse Therapy Plus Immunosuppressive Agent. Med Sci Monit 2017;23:1217-23. [PMID: 28278141 DOI: 10.12659/msm.902442] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Hoffmann S, Siedler J, Brandt AU, Piper SK, Kohler S, Sass C, Paul F, Reilmann R, Meisel A. Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. BMC Neurol 2015;15:265. [PMID: 26701600 DOI: 10.1186/s12883-015-0517-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 2019;7:319. [PMID: 31753014 DOI: 10.1186/s40425-019-0774-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 26.0] [Reference Citation Analysis]
6 Gamez J, Salvado M, Casellas M, Manrique S, Castillo F. Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy. J Neurol Sci. 2017;383:118-122. [PMID: 29246598 DOI: 10.1016/j.jns.2017.10.037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Fan Z, Li Z, Shen F, Zhang X, Lei L, Su S, Lu Y, Di L, Wang M, Xu M, Da Y. Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients. Front Neurol 2020;11:594152. [PMID: 33193063 DOI: 10.3389/fneur.2020.594152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wang S, Breskovska I, Gandhy S, Punga AR, Guptill JT, Kaminski HJ. Advances in autoimmune myasthenia gravis management. Expert Rev Neurother 2018;18:573-88. [PMID: 29932785 DOI: 10.1080/14737175.2018.1491310] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
9 Grisold W, Löscher W, Grisold A. Neurological complications of systemic tumor therapy. Wien Med Wochenschr 2019;169:33-40. [PMID: 30232660 DOI: 10.1007/s10354-018-0654-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Liu F, Wang Q, Chen X. Myasthenic crisis treated in a Chinese neurological intensive care unit: clinical features, mortality, outcomes, and predictors of survival. BMC Neurol 2019;19:172. [PMID: 31324153 DOI: 10.1186/s12883-019-1384-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]